Analysts Offer Insights on Healthcare Companies: Niagen Bioscience (NAGE) and Disc Medicine (IRON)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Niagen Bioscience (NAGE – Research Report) and Disc Medicine (IRON – Research Report) with bullish sentiments.
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Niagen Bioscience (NAGE)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Niagen Bioscience today and set a price target of $12.00. The company’s shares closed last Friday at $5.14.
According to TipRanks.com, Selvaraju is a 5-star analyst with an average return of
Currently, the analyst consensus on Niagen Bioscience is a Strong Buy with an average price target of $16.33.
See the top stocks recommended by analysts >>
Disc Medicine (IRON)
H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Disc Medicine on February 13 and set a price target of $118.00. The company’s shares closed last Friday at $55.95.
According to TipRanks.com, Tsao is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Disc Medicine with a $122.33 average price target, which is a 70.8% upside from current levels. In a report issued on February 3, Morgan Stanley also maintained a Buy rating on the stock with a $120.00 price target.
